The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ulcerative colitis (UC)1,2 In both trials, the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including endoscopic improvement** and histologic-endoscopic mucosal improvement,† were met1,2 UC is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) aff ...

文章核心观点 - 公司的增长平台占据了公司业务的约80%,增长率达到中个位数[10] - 公司预计未来几年将实现高个位数的年收入增长[18] - 公司的创新能力和产品组合为其带来了长期的增长机会[15][16][17] 公司概况 - 公司是一家市值275亿美元的制药巨头[8] - 公司自2012年从雅培(Abbott)分拆独立上市以来,每年都在持续增加股息[7] - 公司的主要产品包括Skyrizi和Rinvoq,这两款产品在上市5年内销售额增长超过50%[12][13] - 公司预计这两款产品到2027年的销售额将超过270亿美元,年复合增长率达19%[14] 财务表现 - 公司2023年受到Humira专利到期的影响,预计EPS将下降19%[20] - 但从2024年开始,公司EPS增长预计将恢复到个位数,并在2026年达到12%[20] - 公司当前的市盈率为13.9倍,略高于10年平均水平13.2倍[19] - 结合4%的股息收益率和未来的增长预期,公司预计可以实现8-10%的年化总回报率[21] 发展前景 - 公司正在加强营销力度和战略合作,以更快地提高市场份额[17] - 公司正在积极拓展神经科学和肿瘤科等新领域,为未来发展带来新的增长动力[15][16] - 公司有望凭借创新能力和强大的产品组合,实现未来多年的双位数EPS增长[23]

For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let’s get some of the bad stuff out of the way first. Biotech stocks – even the established players – can be volatile. A miss in the clinical process to commercialize a therapeutic could lead to significant losses. And there’s really no way of reliably forecasting such outcomes. Plus, the sector isn’t always known for delivering predictable financial performan ...

AbbVie's returns haven't been great this year, but investors shouldn't overlook this promising growth stock. Nvidia (NVDA 2.57%) has been a great stock to own, and it could remain that way for long-term investors. However, the problem is that it's trading at nearly 40 times its future profits. At such a high valuation, it sets a high bar for the business and effectively prices in a lot of future growth already. It could make it difficult for the stock to continue to generate high returns. Even if it does, a ...

bunhill Written by Sam Kovacs. Introduction: Does Selling in May make sense? "Sell in May and go away." This Wall Street adage, with roots going back to 18th century England, has somehow endured the test of time. I've always been fascinated by these seasonal shifts and trends in the market. The original phrase was "Sell in May and go away and come back on St. Leger's day." St. Leger's day usually lands somewhere in the middle of September. The idea was that British investors should sell their shares to enjo ...

PALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis, and treatment of pancreatic cancer, a particularly aggressive and often fatal form of cancer affecting the pancreas. With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts. A recent report from BioSpa ...

Eoneren Introduction Some people on Wall Street are so powerful that whenever they are interviewed, people drop everything to hear what they have to say. One of these people is JPMorgan (JPM) CEO Jamie Dimon, who has a reputation as one of the best banking CEOs in modern history. Since January 1, 2000, his bank has returned 681%, beating the S&P 500 by roughly 220 points. That's a huge deal as it includes the Great Financial Crisis, the pandemic, and last year's banking woes. Data by YCharts With that said, ...

- Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill., May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the acquisition, Landos is now part of AbbVie. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a memb ...

Biotech is one of the most exciting industries to invest in right now. Companies have drugs on the market worth billions and continue to strive to produce the newest and best treatments in modern medicine. Some biotech companies can face volatility as their popularity largely depends on pipeline updates. But some have proven more resilient than others. These three biotech stocks are some of the sector’s most consistently performing stocks. They produce medicines in both the pharma and biotech classes. Despi ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks St ...